ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 25 Oct 2024
Last Updated on 25 Oct 2024
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has has not recommended recombinant zoster vaccine (RZV) for listing on the MOH Subsidised Vaccine List for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in adults 50 years of age or older, and adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. The decision was based on the unfavourable cost-effectiveness of RZV and the absence of a price-volume agreement in the company’s proposal.
Recombinant zoster vaccine prevention of herpes zoster post herpetic neuralgia (25 Oct 2024) PES Recombinant zoster vaccine for preventing shingles and related nerve pain (25 Oct 2024)